RLMD
Price:
$5.44
Market Cap:
$570.60M
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquarter...[Read more]
Industry
Biotechnology
IPO Date
2014-06-20
Stock Exchange
NASDAQ
Ticker
RLMD
According to Relmada Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -4.99. This represents a change of 40.09% compared to the average of -3.56 of the last 4 quarters.
The mean historical PE Ratio of Relmada Therapeutics, Inc. over the last ten years is -1.22. The current -4.99 PE Ratio has changed 40.69% with respect to the historical average. Over the past ten years (40 quarters), RLMD's PE Ratio was at its highest in in the March 2025 quarter at -0.12. The PE Ratio was at its lowest in in the March 2026 quarter at -7.91.
Average
-1.22
Median
-0.42
Minimum
-4.79
Maximum
-0.16
Discovering the peaks and valleys of Relmada Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.60%
Maximum Annual PE Ratio = -0.16
Minimum Annual Increase = -82.15%
Minimum Annual PE Ratio = -4.79
| Year | PE Ratio | Change |
|---|---|---|
| 2025 | -3.33 | 1.60% |
| 2024 | -0.20 | -37.51% |
| 2023 | -0.31 | 90.75% |
| 2022 | -0.16 | -73.86% |
| 2021 | -0.63 | -62.56% |
| 2020 | -1.68 | -64.84% |
| 2019 | -4.79 | 798.06% |
| 2019 | -0.53 | 88.61% |
| 2018 | -0.28 | -10.42% |
| 2017 | -0.32 | -82.15% |
The current PE Ratio of Relmada Therapeutics, Inc. (RLMD) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-1.28
5-year avg
-0.93
10-year avg
-1.22
Relmada Therapeutics, Inc.’s PE Ratio is less than Acrivon Therapeutics, Inc. Common Stock (-0.82), less than PMV Pharmaceuticals, Inc. (-0.79), less than Immunic, Inc. (-2.34), less than TScan Therapeutics, Inc. (-0.81), less than Vaxart, Inc. (4.13), less than Lite Strategy, Inc. (-0.10), less than Fortress Biotech, Inc. (0.72), less than Repare Therapeutics Inc. (-2.59), less than Cibus, Inc. (-1.09), less than Adicet Bio, Inc. (-0.61),
| Company | PE Ratio | Market cap |
|---|---|---|
| -0.82 | $70.19M | |
| -0.79 | $62.40M | |
| -2.34 | $190.84M | |
| -0.81 | $47.64M | |
| 4.13 | $140.01M | |
| -0.10 | $32.51M | |
| 0.72 | $92.68M | |
| -2.59 | $114.24M | |
| -1.09 | $87.79M | |
| -0.61 | $85.63M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Relmada Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Relmada Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Relmada Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Relmada Therapeutics, Inc. (RLMD)?
What is the highest PE Ratio for Relmada Therapeutics, Inc. (RLMD)?
What is the 3-year average PE Ratio for Relmada Therapeutics, Inc. (RLMD)?
What is the 5-year average PE Ratio for Relmada Therapeutics, Inc. (RLMD)?
How does the current PE Ratio for Relmada Therapeutics, Inc. (RLMD) compare to its historical average?